What Role Does Rheumatoid Arthritis Disease Activity Have in Cardiovascular Risk?

Huaranga, Marco Aurelio Ramírez; Sánchez, María Dolores Mínguez; Espina, Miguel Ángel Zarca Díaz de la; Prados, Pedro José Espinosa; Aguilera, Guillermo Romero

doi:10.1016/j.reumae.2017.03.008

Cited by 5 publications

(8 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the average follow-up period of 8 years, 43.9% of the RA group and 37.5% of the OA group had one or more fatal or non-fatal CV events; of these, 31.7% in the RA and 30.9% in the OA group survived. The incidence was not signi cantly different between groups, which is in concordance with most previous studies [31,32,47,49], although the patients with RA included in the study were approximately 5 years younger than those with OA. Compared with data from the Croatian population in 2018, a statistically signi cant difference in CVD deaths was observed for RA but not for OA [52], which may suggest that CV risk estimation or calculators still underestimate risk in patients with RA.…”

Section: Discussionsupporting

confidence: 91%

“…Despite SCORE modi cations, limitations to CV risk estimation and early atherosclerosis detection remain [31]. The lipid paradox and effect of in ammation on lipid particle composition in RA make the interpretation of circulating lipid levels less reliable for use in CV risk prediction models [32]. Due to chronic in ammation, the European Alliance of Associations for Rheumatology (EULAR) guidelines support the use of ultrasound for early screening of asymptomatic carotid plaques [29].…”

Section: Introductionmentioning

confidence: 99%

“…More e cient new therapies with fewer extra-articular manifestations can also affect risk estimation [33]. High-grade uncontrolled in ammation leads to accelerated atherosclerosis and early vascular damage, which directly increases CV risk and early CVD manifestations [32,34]. The cumulative time spent in RA ares signi cantly impacts CV risk; Myasoedova et al showed that CV risk was higher in patients with RA who spent more time in medium (hazard ratio [HR] 1.08; 95% CI, 0.98-1.20) and high disease activity (HR 1.18; 95% CI, 1.06-1.31) than in those with more time in lower activity [35].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk for cardiovascular disease development in rheumatoid arthritis

Bedeković,

Bošnjak,

Bilić-Ćurčić

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Patients with rheumatoid arthritis have significant cardiovascular mortality and morbidity. Objective To investigate the effects of chronic inflammation in rheumatoid arthritis on cardiovascular morbidity association with cardiovascular risk factors risk factors. Mortality report is secondary just to show trends without sufficient statistical power as it is accidental endpoint. Methods A total of 201 individuals without previous cardiovascular disease, 124 with rheumatoid arthritis (investigation group) and 77 with osteoarthritis (control group), were included in the study and followed up for an average of 8 years to assess the development of fatal or non-fatal cardiovascular diseases. The incidence and prevalence of cardiovascular risk factors were also investigated. Results The total incidence of one or more fatal or nonfatal cardiovascular events was 43.9% in the investigation group and 37.5% in the control group. Of these patients, 31.7% and 30.9% survived cardiovascular events in the investigation and control groups, respectively. The most common cardiovascular disease among participants who completed the study and those who died during the study was chronic heart failure. The results of the subgroup analysis showed that strict inflammation control plays a central role in lowering cardiovascular risk.. Conclusion A multidisciplinary approach to these patients is of paramount importance, especially with the cooperation of immunologists and cardiologists for early detection, prevention, and management of cardiovascular risks and diseases.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk for cardiovascular disease development in rheumatoid arthritis

Bedeković,

Bošnjak,

Bilić-Ćurčić

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“… 92 A number of studies included in this review found similar results concerning RA-derived autoantibodies and atherosclerosis. 51 , 55 , 84 , 85 , 87 An interesting phenomenon was reported by Jacobsen et al , who found polymorphic variations in the mannose-binding lectin gene (MBL) were associated with high scores of RA disease activity, C-reactive protein-based DAS28, and physical disability in anti-CCP-positive RA patients. 115 MBL, a serum protein, plays an instrumental role in regulating innate immunity by binding to repeating sugar motifs to activate the complement system via MBL-associated serum proteases.…”

Section: Discussionmentioning

confidence: 84%

Accelerated atherosclerosis in rheumatoid arthritis: a systematic review

Thomas

Gorantla

2022

F1000Res

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a highly prevalent, chronic inflammatory condition of the synovial joints that affects approximately 1% of the global population. The pathogenesis of RA is predominantly inflammatory in nature, thereby accelerating the co-occurrence of other immunoinflammatory conditions such as atherosclerosis. Apart from traditional cardiovascular risk factors, RA patients possess a multitude of other factors that predispose them to early atherosclerotic disease. The aim of this systematic review is to assess the prevalence of premature atherosclerosis in RA patients and elucidate the role that proinflammatory cytokines, neutrophil extracellular traps, RA-related autoantibodies, and endothelial dysfunction play in the pathophysiology of RA-mediated atherosclerosis. We also discussed novel biomarkers that can be used to predict early atherosclerosis in RA. Methods: This review followed the PRISMA guidelines to select and analyze relevant articles. A literature search for articles was performed on February 25, 2022, through three research databases including PubMed, ProQuest, and ScienceDirect. The query used to identify relevant publications was “Rheumatoid arthritis and atherosclerosis” and the search duration was set from 2011-2022. Relevant articles were selected based on the inclusion and exclusion criteria. Results: Our initial search generated 21,235 articles. We narrowed our search according to the inclusion and exclusion criteria. After assessing eligibility based on the full content of the articles, 73 articles were ultimately chosen for this review. Conclusion: There is a high prevalence of accelerated atherosclerosis among RA patients. We found evidence to explain the role of proinflammatory cytokines, neutrophil extracellular traps, RA-related autoantibodies, and endothelial dysfunction in the pathophysiology RA-mediated atherosclerosis. Therapies targeting either the inflammatory load or traditional CV risk-factors seem to improve vascular outcomes in RA patients. Novel markers of atherosclerosis in RA may be useful in predicting premature atherosclerosis and serve as new targets for therapeutic intervention.

show abstract

“…Despite SCORE modifications, limitations to CV risk estimation and early atherosclerosis detection remained [ 31 ]. The lipid paradox and effect of inflammation on lipid particle composition in RA make the interpretation of circulating lipid levels less reliable for use in CV risk prediction models [ 32 ]. More efficient new therapies with fewer extra-articular manifestations can also affect risk estimation [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

Risk for cardiovascular disease development in rheumatoid arthritis

Bedeković,

Bošnjak,

Bilić-Ćurčić

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Patients with rheumatoid arthritis have significant cardiovascular mortality and morbidity. Objective To investigate the effects of chronic inflammation in rheumatoid arthritis on cardiovascular morbidity association with cardiovascular risk factors risk factors. Mortality report is secondary just to show trends without sufficient statistical power as it is accidental endpoint. Methods A total of 201 individuals without previous cardiovascular disease, 124 with rheumatoid arthritis (investigation group) and 77 with osteoarthritis (control group), were included in the study and followed up for an average of 8 years to assess the development of fatal or non-fatal cardiovascular diseases. The incidence and prevalence of cardiovascular risk factors were also investigated. Results The total incidence of one or more fatal or nonfatal cardiovascular events was 43.9% in the investigation group and 37.5% in the control group. Of these patients, 31.7% and 30.9% survived cardiovascular events in the investigation and control groups, respectively. The most common cardiovascular disease among participants who completed the study and those who died during the study was chronic heart failure. The results of the subgroup analysis showed that strict inflammation control plays a central role in lowering cardiovascular risk. Conclusion A multidisciplinary approach to these patients is of paramount importance, especially with the cooperation of immunologists and cardiologists for early detection, prevention, and management of cardiovascular risks and diseases.

show abstract

What Role Does Rheumatoid Arthritis Disease Activity Have in Cardiovascular Risk?

Cited by 5 publications

References 54 publications

Risk for cardiovascular disease development in rheumatoid arthritis

Risk for cardiovascular disease development in rheumatoid arthritis

Accelerated atherosclerosis in rheumatoid arthritis: a systematic review

Risk for cardiovascular disease development in rheumatoid arthritis

Contact Info

Product

Resources

About